Ralmitaront

DB19128InvestigationalSmall molecule

Ralmitaront is under investigation in clinical trial NCT04512066 (A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or...

Mechanism: Pharmacologically active on Trace amine-associated receptor 1
Curator reviewed
Formula / weight: C₁₇H₂₂N₄O₂ · 314.389 g/mol (avg)
Also known as: 1h-pyrazole-3-carboxamide, 5-ethyl-4-methyl-n-(4-(2s)-2-morpholinylphenyl)- · 5-ethyl-4-methyl-n-(4-((2s)-morpholin-2-yl)phenyl)-1h-pyrazole-3-carboxamide
Code names: RG-7906 · RO-6889450

Resolves to

Compound

UNIIQA8MW1Q80PCAS2133417-13-5ChEMBLCHEMBL4594376

Structure

InChIKeyXHHXGKRFUPEPFM-OAHLLOKOSA-NSMILES[H][C@@]1(CNCCO1)C1=CC=C(NC(=O)C2=NNC(CC)=C2C)C=C1

Targets

Q96RJ0TAAR1

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ralmitaront, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account